Skip to content
HowShorted

Karyopharm Therapeutics Inc. short interest in 2020

In 2020, Karyopharm Therapeutics Inc.'s disclosed short interest ran from 15.32% of shares outstanding on 15 Jan 2020 to 20.96% on 31 Dec 2020, a change of +5.64 percentage points. The year's high was 22.83% on 15 Jul 2020 and its low 15.32% on 15 Jan 2020, averaging 20.10% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.49 days on 15 Oct 2020. Full history: Karyopharm Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Karyopharm Therapeutics Inc. in 2020

2020 in figures

Start of year
15.32% (15 Jan 2020)
End of year
20.96% (31 Dec 2020)
Change
+5.64 pp
High
22.83% (15 Jul 2020)
Low
15.32% (15 Jan 2020)
Average
20.10%
Highest days to cover
17.49 (15 Oct 2020)
SEC filings marked
10

Every report in 2020

Karyopharm Therapeutics Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202015.32%9.44results (8-K)
31 Jan 202020.59%11.89
14 Feb 202019.56%15.71results (8-K)
28 Feb 202019.87%10.1510-K filed
13 Mar 202018.89%3.10
31 Mar 202020.25%8.37
15 Apr 202021.78%14.06
30 Apr 202018.47%13.99
15 May 202018.20%7.9710-Q filed, results (8-K)
29 May 202018.95%9.10
15 Jun 202019.81%9.19
30 Jun 202021.31%6.03
15 Jul 202022.83%10.49results (8-K)
31 Jul 202021.18%11.28
14 Aug 202021.07%9.0810-Q filed, results (8-K)
31 Aug 202019.43%13.60
15 Sep 202019.60%13.56
30 Sep 202020.37%12.89
15 Oct 202021.02%17.49
30 Oct 202021.38%16.41
13 Nov 202021.09%10.6610-Q filed, results (8-K)
30 Nov 202020.38%13.76
15 Dec 202019.98%7.97
31 Dec 202020.96%4.78

See also: Karyopharm Therapeutics Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.